Abstract 15534: Identification of Narciclasine, a Potential Drug to Treat PAH by Unbiased Pharmaco-Transcriptomic Study
ANTONELLA ABI SLEIMAN(Institut universitaire de cardiologie et de pneumologie de Québec), François Potus(Queen's University), Sandra Martineau(Canadian Heart Research Centre), Steeve Provencher(Institut universitaire de cardiologie et de pneumologie de Québec), Sébastien Bonnet(Institut universitaire de cardiologie et de pneumologie de Québec), Sarah‐Eve Lemay(SNC-Lavalin (Canada)), Charlotte Romanet(Canadian Heart Research Centre), Olivier Boucherat, EL-Kabbout Reem, Charlie Théberge(Canadian Heart Research Centre), Sandra Breuils Bonnet(Université Laval), Mabrouka Salem(King Khalid University), Alice Bourgeois, Yann Grobs(Institut universitaire de cardiologie et de pneumologie de Québec)
Cited by 0
Related Papers
A Mitochondria-K+ Channel Axis Is Suppressed in Cancer and Its Normalization Promotes Apoptosis and Inhibits Cancer Growth
|Cancer Cell|2007|1.5k
Novel Mutations and Decreased Expression of the Epigenetic Regulator <i>TET2</i> in Pulmonary Arterial Hypertension
|Circulation|2020|120
Defining the clinical validity of genes reported to cause pulmonary arterial hypertension
|Genetics in Medicine|2023|73
Oxidized DNA Precursors Cleanup by NUDT1 Contributes to Vascular Remodeling in Pulmonary Arterial Hypertension
|American Journal of Respiratory and Critical Care Medicine|2020|34
ATP citrate lyase drives vascular remodeling in systemic and pulmonary vascular diseases through metabolic and epigenetic changes
|Science Translational Medicine|2024|33